Sarepta Therapeutics Elevidys Patient Deaths Lawsuits
Analysis based on 44 articles · First reported Jun 27, 2025 · Last updated Aug 25, 2025
The market is significantly impacted by the ongoing class action lawsuits against Coya Therapeutics, as the company's stock price has plummeted due to revelations of patient deaths associated with its key product, Delandistrogene moxeparvovec. This event highlights the substantial risks and potential liabilities faced by biotechnology companies when product safety issues emerge, leading to investor losses and increased regulatory scrutiny.
Coya Therapeutics, a biopharmaceutical company, is facing multiple class action lawsuits from law firms including Bleichmar Fonti & Auld LLP, Levi & Korsinsky, and Robbins Geller Rudman & Dowd LLP. These lawsuits allege that Coya Therapeutics and its senior executives made false and misleading statements regarding the safety of its Duchenne muscular dystrophy gene therapy, Delandistrogene moxeparvovec. The controversy stems from the deaths of three patients who received Delandistrogene moxeparvovec or related investigational treatments, all succumbing to acute liver failure. These deaths, announced on March 18, June 15, and July 17, 2025, led to significant drops in Coya Therapeutics's stock price, with declines of over 27%, 42%, and 40% respectively. The United States — Food and Drug Administration has also issued a Safety Communication and is investigating the risks associated with Delandistrogene moxeparvovec. The lawsuits, pending in the United States — United States District Court for the Northern District of California, seek to recover losses for investors who purchased Coya Therapeutics securities between June 22, 2023, and June 24, 2025, with an August 25, 2025, deadline for investors to seek lead plaintiff appointment.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard